Please assess the completion status of the following clinical trial:

Trial Title: Perineural Steroids for Peripheral Nerve Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* elective robotic medial MAKO partial knee arthroplasty~* agreed to a regional anesthesia technique~Exclusion Criteria:~* contraindications to regional anesthesia~* presence of a progressive neurological deficit~* a pre-existing coagulopathy, infection~* insulin and non-insulin dependent diabetes mellitus~* systemic use of corticosteroids within 30 days of surgery~* chronic use of an opioid analgesic (\>3 months or a combined total of more than 40 mg Oxycodone equivalents a day)~* pregnancy~* a prior history of an adverse event (for example: psychosis) or an allergy to dexamethasone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- 4 mg Perineural Dexamethasone Group (Type: EXPERIMENTAL): 4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
- 1 mg Perineural Dexamethasone Group (Type: EXPERIMENTAL): 1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
- Placebo Group (Type: PLACEBO_COMPARATOR): This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.

Based on this trial design, predict the completion outcome and termination type (if applicable).